Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
Completed
National Institute of Mental Health (NIMH)
Phase 3
2001-04-01
This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in
very young children. The medication being used is methylphenidate (Ritalin); it is being
studied to determine its safety and how well it works to treat ADHD in preschool-age children
(3-5.5 year olds).
Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
Completed
New York State Psychiatric Institute
Phase 3
2001-04-01
This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in
very young children. The medication being used is methylphenidate (Ritalin); it is being
studied to determine its safety and how well it works to treat ADHD in preschool-age children
(3-5.5 year olds).
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
Completed
National Institute of Mental Health (NIMH)
N/A
2001-10-01
This study will evaluate the efficacy and safety of methylphenidate for treating
hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with
Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and
Drug Administration for the treatment of children and adolescents with Attention Deficit
Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD
symptoms in PDD are limited. Children and adolescents who do not show a positive response to
methylphenidate will be invited to participate in a pilot study of the non-stimulant
medication guanfacine (Tenex).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
